Bioventus (BVS) Amortization of Deferred Charges (2020 - 2021)
Bioventus (BVS) posted Amortization of Deferred Charges of $136000.0 for Q2 2021, little changed on a QoQ basis from $136000.0 in Q1 2020, and little changed year-over-year from $136000.0 in Q2 2020.
Bioventus (BVS) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Bioventus' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $136000.0 for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Bioventus | 837.84 Mn | 801.99 Mn | 90.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2021 | 136,000.00 |
| Apr 3, 2021 | 136,000.00 |
| Mar 28, 2020 | 136,000.00 |
| Mar 28, 2020 | 136,000.00 |